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Patients with heart failure (HF) have diaphragm abnormalities that contribute to disease
morbidity and mortality. Studies in animals suggest that reactive oxygen species (ROS)
cause diaphragm abnormalities in HF. However, the effects of HF on ROS sources,
antioxidant enzymes, and protein oxidation in the diaphragm of humans is unknown.
NAD(P)H oxidase, especially the Nox2 isoform, is an important source of ROS in the
diaphragm. Our main hypothesis was that diaphragm from patients with HF have
heightened Nox2 expression and p47phox phosphorylation (marker of enzyme activation)
that is associated with elevated protein oxidation. We collected diaphragm biopsies
from patients with HF and brain-dead organ donors (controls). Diaphragm mRNA levels
of Nox2 subunits were increased 2.5–4.6-fold over controls (p < 0.05). Patients also
had increased protein levels of Nox2 subunits (p47phox, p22phox, and p67phox) and
total p47phox phosphorylation, while phospho-to-total p47phox levels were unchanged.
The antioxidant enzyme catalase was increased in patients, whereas glutathione
peroxidase and superoxide dismutases were unchanged. Among markers of protein
oxidation, carbonyls were increased by ∼40% (p < 0.05) and 4-hydroxynonenal and
3-nitrotyrosines were unchanged in patients with HF. Overall, our findings suggest that
Nox2 is an important source of ROS in the diaphragm of patients with HF and increases
in levels of antioxidant enzymes are not sufficient to maintain normal redox homeostasis.
The net outcome is elevated diaphragm protein oxidation that has been shown to cause
weakness in animals.
Keywords: diaphragm, carbonyls, weakness, inspiratory muscles, NOX2
INTRODUCTION
Patients with end-stage heart failure (HF) have respiratory complications that contribute to disease
morbidity and mortality. The incidence of pneumonia in end-stage HF patients who receive a heart
transplant is 15–20% and 5% of patients have prolonged respiratory failure post-heart transplant
(Lenner et al., 2001). The cause of pneumonia and respiratory failure in end-stage HF patients
is multifactorial. In this context, inspiratory muscle abnormalities in patients with end-stage HF
can play a critical role in respiratory complications (Kelley and Ferreira, 2016). For instance,
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pre-operative inspiratory muscle strength training reduces the
incidence of post-operative pulmonary complications in “high-
risk” patients, including those with HF, undergoing coronary
artery bypass graft (Hulzebos et al., 2006).
The primary inspiratory muscle is the diaphragm, which
is necessary for normal ventilatory and expulsive behaviors
that promote airway clearance (Sieck and Fournier, 1989;
Mantilla and Sieck, 2013). Diaphragm dysfunction has been
documented in animal models of HF, being characterized by
atrophy and contractile impairments that diminish force and
power capabilities (Howell et al., 1995; Stassijns et al., 1998;
van Hees et al., 2007; Ahn et al., 2015; Kelley and Ferreira,
2016). The diaphragm of end-stage HF patients also shows
ultra-structural and myofibrillar protein alterations that suggest
metabolic and contractile abnormalities (Lindsay et al., 1996).
However, less is known about the underlying mechanisms of
diaphragm dysfunction in end-stage HF.
Excess reactive oxygen species (ROS) and redox imbalance
play a causal role in diaphragm dysfunction in animal models
of HF (Supinski and Callahan, 2005; Ahn et al., 2015). An
important source of ROS in the diaphragm is the Nox2 isoform
of NAD(P)H oxidase (Pal et al., 2013; Loehr et al., 2014; Bost
et al., 2015). A functionally assembled Nox2 enzyme complex
consists of several subunits (Nox2, p22phox, p67phox, p40phox,
Rac1/2, and p47phox), and enzyme activation requires p47phox
phosphorylation (Javesghani et al., 2002; Lassègue et al., 2012;
Pal et al., 2013; Ferreira and Laitano, 2016). Diaphragm p47phox
phosphorylation is increased in mice with HF, and genetic
deletion of p47phox prevents excess ROS release and contractile
dysfunction in diaphragm of mice with HF (Ahn et al., 2015).
These findings in mice suggest a pivotal role for Nox2-derived
ROS on diaphragm dysfunction in HF.
Diaphragm antioxidant enzymes are unchanged (Ahn et al.,
2015) or elevated in animal models of HF (Bowen et al., 2015b;
Mangner et al., 2015). The increase in antioxidant enzymes
may reflect a compensatory response to scavenge excess ROS.
However, these compensatory responses appear insufficient to
maintain cellular redox homeostasis as markers of protein
oxidation are elevated in diaphragm of HF animals (acute Bowen
et al., 2015a and chronic models Supinski and Callahan, 2005;
Coirault et al., 2007). This is relevant because heightened ROS
and protein oxidation promote diaphragm atrophy and impair
contractile function (Ferreira and Reid, 2008; Powers et al., 2011).
Despite advances in understanding the causes and role of
redox imbalance on diaphragm dysfunction in animal models
of HF, very little is known about ROS sources, antioxidant
enzymes, and protein oxidation in the diaphragm of patients.
We tested the hypotheses that diaphragm from patients with
end-stage HF show heightened Nox2 subunit levels and p47phox
phosphorylation with unchanged protein levels of antioxidant
enzymes which results in elevated markers of protein oxidation.
METHODS
Human Subjects
We obtained diaphragm biopsies from patients with HF with
reduced ejection fraction who underwent surgery for heart
transplant or placement of left ventricular assist device. Patients
were informed of the nature and purpose of the study and signed
a written consent in accordance with the Declaration of Helsinki.
Control subjects were brain-dead organ donors whose family
consented to the diaphragm biopsies. The protocol and sample
analyses were approved by the Institutional Review Boards of the
University of Kentucky or University of Florida.
Tissue Collection
The cardiothoracic surgeons (MRB and CWH) obtained
diaphragm biopsies and placed them in ice- cold sterile saline.
The samples were rapidly processed in the operating room to
clear any visible connective tissue and excess blood, then frozen
in liquid nitrogen and stored at −80◦C for further processing
as described below. All procedures for tissue collection and
analyses were approved by the Institutional Review Boards of the
University of Kentucky or University of Florida.
qPCR
We isolated total RNA from human diaphragm tissue with
Trizol reagent. We then used Ambion RETROscript First Strand
Synthesis Kit (Life Technologies, Carlsbad, CA, USA) to generate
cDNA from 1 µg of RNA. The cDNA was then used as template
for qRT-PCR (7300 real-time PCR system, Applied Biosystems,
Austin, TX). We used TaqMan R© PCR assay primers from Life
Technologies targeting the following genes and NCBI Reference
Sequence numbers: Nox2 (CYBB, NM_000397.3), p47phox (NCF1
NM_000265.5), Rac1 (RAC1, NM_006908.4), p22phox (CYBA,
NM_000101.3), p67phox (NCF2, NM_000433.3), and p40phox
(NCF4, NM_000631.4). Gene expression quantification was
performed using the relative standard-curve method, and all
data were normalized to the gene expression of 18S (GeneBank
NM_X03205.1) and reported relative to the control group.
Immunoblotting
We loaded ∼10–50 µg of protein into 4–20% stain-free TGX
gels (Bio-Rad Laboratories) and performed electrophoresis at
230 V for 40 min on ice. We scanned the gel to quantify total
proteins (Gel DocTM EZ Imager, Bio-Rad Laboratories) and
then transferred the proteins to a nitrocellulose membrane at
100 mA overnight at 4◦C. We blocked the membrane using Li-
COR Blocking Buffer for 1 h at room temp and subsequently
probed with primary antibodies. Asmarkers of protein oxidation,
we measured protein carbonyls (OxySelectTM Protein Carbonyl
Immunoblot kit, Cell Biolabs), 4-hydroxynonenal (4-HNE,
Ab46545, AbCam) adducts, and 3-nitrotyrosines (3-NT, 189542,
Cayman Chemical). To probe for sources of ROS, we used
primary antibodies targeting Nox2 (CYBB, 1:500 dilution, sc-
5827, Santa Cruz), p22phox (CYBA, 1:50 dilution, FL-195,
Santa Cruz), p67phox (NCF2, 1:50 dilution, sc-7663, Santa
Cruz), Rac1 (RAC1, 1:1000 dilution 05-389, Millipore), p47phox
(NCF1, 1:1000 diltuion, SAB2500674, Sigma-Aldrich), and
phosphorylated p47phox at serine residues 345 (orb126026,
Biobyrt), 370 (A1171, Assay Biotech), 359 (A1172, Assay
Biotech), 328 (A1161, Assay Biotech), and 304 (A1160, Assay
Biotech). The dilution for antibodies targeting serine residues was
1:1000. For antioxidant enzymes, we used antibodies targeting
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superoxide dismutase isoform 1 (SOD1; 1:500 dilution, FL-
154, Santa Cruz), SOD2 (1:500 dilution, FL-122, Santa Cruz),
catalase (1:1000 dilution, Ab16731, Abcam), and glutathione
peroxidase (1:1000 dilution, Ab108427, Abcam). We diluted
the primary antibodies in LiCor Blocking Buffer, incubated the
membranes for 72 h at 4◦C or 1 h at room temperature, and
washed in TBS-T (Tris-buffered saline with 0.1% Tween) 4 ×
5 min each. We then incubated the membranes in secondary
antibodies (IR Dye, LI-COR) in Li-COR Blocking Buffer for
1 h at room temp, followed by 3 × 5 min washes in TBS-T
and a 5 min rinse in TBS. We dried the membranes in an
incubation chamber at ∼37◦C for 15 min and scanned the
fluorescence signal using an Odyssey Infrared Imaging system
(LI-COR, Lincoln, NE). We quantified the immunoblot signal
using Image Studio Lite R© (Li-COR) and the abundance of total
protein in each gel lane using ImageLab (Bio-Rad Laboratories).
The immunoblot signal of each target protein was normalized
to the total protein measured in corresponding gel lanes. These
procedures are consistent with recent recommendations for
data analysis of Western blots using fluorescence methods
and stain- free gels (Eaton et al., 2013; Murphy and Lamb,
2013).
Statistical Analysis
We performed statistical analysis using SigmaPlot v.12.5 (Systat
Software, San Jose, CA). For specific comparisons, we used t-test
or Mann-Whitney rank sum test for data that failed normality
(Shapiro-Wilk test). Non-parametric data are presented as
median ± interquartile range and shown in box and whisker
plots. We declared statistical significance when P < 0.05.
RESULTS
Patient characteristics are detailed in Table 1. In summary,
patients exhibited HF caused by ischemic (n = 5) and non-
ischemic cardiomyopathy (n= 6).
Diaphragm mRNA levels of Nox2, p22phox, p47phox, p67phox,
and p40phox were increased with median values ranging from
2.5- to 4.6-fold over controls (Figure 1). The protein levels of
Nox2, p47phox, p22phox, and p67phox were also increased in
diaphragm of HF patients, while protein levels of Rac1 was not
significantly changed (Figure 1). We were not able to detect
p40phox via immunoblot in the diaphragm, which is consistent
with a previous study (Javesghani et al., 2002).
TABLE 1 | Patient characteristics.
Control HF
Age (year) 29 ± 6 50 ± 5*
Body weight (kg) 87 ± 15 90 ± 7
Height (m) 1.65 ± 0.01 1.79 ± 0.03
Ejection fraction (%) – 20 (9)*
Males/Females 0/3 10/1
HF, heart failure. Data are mean ± SE. Ejection fraction is shown as median (interquartile
range) from 3 controls and 6 patients. *P < 0.05 compared to control.
Phosphorylation of p47phox promotes activation of Nox2
(El-Benna et al., 2009; Lassègue et al., 2012), thus we
examined the phosphorylation status of p47phox using antibodies
against specific phosphorylated serine residues. We found
that phosphorylation at Ser328, Ser345, Ser359, and Ser370
were increased in diaphragm of HF patients compared to
controls when normalized to total protein (Figure 2). When we
normalized the phosphorylated signal from each serine residue
to the total p47phox signal, there was no difference in phospho-
to-total p47phox between control and HF patients (Figure 2).
This suggests that the total abundance of p47phox protein in the
phosphorylated state was elevated, whereas the “percentage” of
phosphorylated p47phox was unchanged.
We measured the protein level of key cytosolic and
mitochondrial antioxidant enzymes (Figure 3). Catalase levels
were increased 2.2-fold over controls (P < 0.05), whereas the
levels of glutathione peroxidase (P = 0.15), SOD1 (P = 0.48),
and SOD2 (P = 0.22) were unchanged in the diaphragm of HF
patients.
Despite increased levels of catalase, redox imbalance in
diaphragm from patients was manifested by increased (∼40%)
protein carbonyls, while 4-HNE and 3-NTwere unchanged in the
diaphragm of end- stage HF patients (Figure 4).
DISCUSSION
Our study shows that diaphragm of patients with end-stage HF
have elevated mRNA and protein levels of Nox2 subunits that
is accompanied by increased p47phox phosphorylation, which is
consistent with Nox2 activation. The antioxidant enzyme catalase
was also increased in diaphragm of patients, while superoxide
dismutases and glutathione peroxidase were unchanged. These
findings suggest disrupted redox homeostasis in the diaphragm
of patients with end-stage HF, which are confirmed by elevated
levels of protein carbonyls.
The enzyme Nox2 is emerging as an important source of
oxidants that cause diaphragm abnormalities in animal models
of diseases, including muscular dystrophy (Whitehead et al.,
2010; Pal et al., 2014; Henriquez-Olguin et al., 2015) and HF
(Ahn et al., 2015). The functionally assembled Nox2 complex
includes several subunits (Nox2, p47phox, p22phox, p40phox,
p67phox, and Rac1 Bedard and Krause, 2007; Lassègue et al.,
2012). We observed that mRNA levels of several Nox2 subunits
were increased in the diaphragm of end-stage HF patients, with
p47phox subunit having the highest elevation (Figure 1).
Increased p47phox mRNA was translated into higher protein
abundance compared to control (Figure 1). Similarly, we have
found heightened protein levels of p47phox in the diaphragm
of mice with HF (Ahn et al., 2015). It is unclear whether
elevated p47phox is sufficient to heighten Nox2 activity in skeletal
muscle cells. Overexpression of p47phox increases Nox2 activity
in glial cells (Lavigne et al., 2001). Thus, it is possible that
skeletal muscle cells have a constitutive, p47phox-dependent Nox2
activity.
The canonical pathway for Nox2 activation involves p47phox
phosphorylation at serine residues that releases auto-inhibition
Frontiers in Physiology | www.frontiersin.org 3 January 2017 | Volume 7 | Article 686
Ahn et al. Nox2 and Protein Oxidation in Heart Failure
FIGURE 1 | Diaphragm Nox2 mRNA and protein levels are increased in patients with end-stage HF. mRNA levels (A,C) and protein (B,D) of Nox2 subunits.
Controls (open boxes; n = 3) and HF patients (gray boxes; n = 9–11). (C,D) are individual data from patients normalized to average of controls (dotted line), as in
(A,B). (E) Representative immunoblots and protein gel. *P < 0.05 by Mann-Whitney test.
of membrane- and subunit-binding domains (El-Benna et al.,
2009; Drummond et al., 2011; Lassègue et al., 2012). The C-
terminal domain of p47phox contains 11 serine residues between
amino acids 303–379 that encompasses the auto-inhibitory
region. Point mutations have revealed six serine residues of
p47phox that are required for full activation of Nox2: Ser303,
Ser304, Ser328, Ser359, Ser370, and Ser379 (reviewed in El-
Benna et al., 2009). We found that total levels of phosphorylated
Ser328, Ser345, Ser359, and Ser370 were elevated in diaphragm
of patients with end- stage HF (Figure 2). When we calculated
the phospho-to-total p47phox ratio, differences between HF
and controls were not statistically significant (Figure 2C).
These findings suggest that increased “absolute” levels of
phosphorylated p47phox accompanied the heightened expression
of total p47phox. However, the “percentage” (or relative levels)
of p47phox protein in the phosphorylated state was unchanged.
Typically, an increase in relative levels/percentage of p47phox
phosphorylation (i.e., elevated phospho-to-total p47phox) is
considered an indicator of Nox2 activation (Isabelle et al., 2005).
In the context of elevated levels of total p47phox, unchanged
phospho-to-total p47phox ratio should also heighten Nox2
activation because phosphorylated p47phox proteins are more
abundant. Biologically, the absolute amount of phosphorylated
p47phox would dictate Nox2 activity. Therefore, we consider
that Nox2 activity is likely increased in diaphragm of end-stage
HF patients. However, the unchanged relative levels/percentage
of phospho-p47phox has implications regarding mechanisms of
Nox2 activation. Our data suggest that the activity of kinases that
phosphorylate p47phox is not necessarily elevated in diaphragm
of patients with end-stage HF. It is possible that other pathways
of p47phox signaling (e.g., arachidonic acid) or overexpression
per se mediate Nox2 activation in the diaphragm (Ferreira
and Laitano, 2016). Alternatively, enhanced diaphragm p47phox
phosphorylation may be involved in the pathophysiology of
diaphragm dysfunction at earlier stages of the disease.
We have not tested Nox2 activity in our study because our
tissue collection method (flash freezing) does not lend the sample
suitable for reliable measurements of activity, as per recent
recommendations (Rezende et al., 2016). We have found, in
diaphragm of mice with HF, increases in total p47phox and
phospho-to-total p47phox that are consistent with increases in
Nox2 activity (Ahn et al., 2015). Indeed, knockout of p47phox
prevented excess diaphragm ROS emission suggesting Nox2 as
a major source of pathological diaphragm oxidants in HF (Ahn
et al., 2015). Overall, our data in humans and animals suggest
elevated Nox2 activity in patients with HF.
A decrease in protein levels or intrinsic activity of antioxidant
enzymes will contribute to ROS accumulation that disrupts
cellular redox balance. Major intracellular antioxidant enzymes
include catalase, glutathione peroxidase, and superoxide
dismutases (SOD1 and SOD2). Patients had increased levels
of catalase, whereas there was no statistical difference in the
Frontiers in Physiology | www.frontiersin.org 4 January 2017 | Volume 7 | Article 686
Ahn et al. Nox2 and Protein Oxidation in Heart Failure
FIGURE 2 | Levels of serine phosphorylation of p47phox in diaphragm of patients with end-stage HF. (A) representative images of immunoblots, (B,D) levels
of phosphorylated p47phox normalized to total protein loaded into gel lane, (C,E) levels of phosphorylated p47phox normalized to immunoblot signal of total p47phox
(from this figure). Controls (open boxes; n = 3) and HF patients (gray boxes; n = 9–11). Panels D and E are individual data from patients normalized to average of
controls (dotted line)—y-axis labels as in (B,C), respectively. Representative protein gels are similar to that shown in Figure 1. *P < 0.05 by Mann-Whitney test.
levels of GPX, SOD1, and SOD2 between patients and controls
(Figure 3). This outcome is likely due to our limited sample size
and large variability in the human diaphragm data. In animal
models of HF with reduced ejection fraction, diaphragm levels of
SOD1 or SOD2 were either unchanged (Ahn et al., 2015; Laitano
et al., 2016) or elevated (Mangner et al., 2015), whereas the
activity of GPX was increased (Mangner et al., 2015) and catalase
was unchanged (Mangner et al., 2015). Nonetheless, diaphragm
catalase activity was increased in a model of HF with preserved
ejection fraction (Bowen et al., 2015b). In general, our data in
patients and studies in animals suggest that heightened protein
oxidation in the diaphragm induced by HF cannot be explained
by a decrease in the protein levels or activity of antioxidant
enzymes. Heightened diaphragm antioxidant enzyme levels in
HF might be a compensatory adaptation aimed to maintain
redox balance when ROS production is increased. However, our
findings suggest that any compensatory response is insufficient
to maintain normal protein oxidation levels in patients with
end-stage HF.
Protein carbonyls, a marker of oxidation, were elevated in
the diaphragm of end-stage HF patients (Figure 4). These results
corroborate previous findings in animals with severe HF induced
by aortic stenosis (Coirault et al., 2007) or in the early stages post-
myocardial infarction (Supinski and Callahan, 2005; Bowen et al.,
2015a), but disagrees with data from our group in rats and mice
with moderate HF in the later stages post-myocardial infarction
(Ahn et al., 2015; Laitano et al., 2016). We speculate that the
increase in diaphragm protein carbonyls in chronic HF is related
to disease severity. This concept is supported by progressive
increases in systemic markers of oxidation in groups of patients
going from NYHA Class I to IV (Belch et al., 1991; Nishiyama
et al., 1998).
Excess oxidation can contribute to diaphragm abnormalities
due to protein degradation as well as impaired function
of excitation-contraction coupling and sarcomeric proteins.
Oxidation enhances protein degradation by calpain, caspase-3,
and the proteasome (Grune et al., 2003; Moylan and Reid, 2007;
Smuder et al., 2010). Calpain and proteasome activity are elevated
in diaphragm of HF rats (Dominguez andHowell, 2003; vanHees
et al., 2008a), and proteasome inhibition prevents myofibrillar
protein degradation and attenuates diaphragm weakness in
HF rats (van Hees et al., 2008a). Regarding protein function,
carbonylation of sarcomeric proteins in vitro impairs actomyosin
cross- bridge kinetics and, in general, exposure to oxidants
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depresses diaphragm force and shortening velocity (Perkins et al.,
1997; Callahan et al., 2001; Coirault et al., 2007). These functional
outcomes are consistent with impaired diaphragm contractile
FIGURE 3 | Diaphragm protein levels of antioxidant enzymes.
(A) Representative immunoblots. (B) Grouped data from control (n = 3) and all
patients with HF (n = 11). (C) Individual data from patients with ischemic and
non-ischemic cardiomyopathy. Representative protein gels are similar to that
shown in Figure 1. *P < 0.05 vs. control by Mann-Whitney test.
properties in HF animals (Lecarpentier et al., 1998; Coirault et al.,
2007; van Hees et al., 2007, 2008b; Empinado et al., 2014; Ahn
et al., 2015), which are prevented by pharmacologic antioxidants
(Supinski and Callahan, 2005; Laitano et al., 2016) or knockout
of p47phox (Ahn et al., 2015).
Limitations
There are several limitations in our study that must be considered
for data interpretation. These limitations include: (A) age and sex
of controls and patients: Patients in the HF group were mostly
males with both ischemic and non-ischemic cardiomyopathy,
while controls were all females and younger than HF patients.
Inspiratory muscle weakness and diaphragm abnormalities are
relevant for patients with ischemic and non-ischemic HF
(Ambrosino et al., 1994; Lindsay et al., 1996; Tikunov et al.,
1997; Daganou et al., 1999; Filusch et al., 2011) as well as male
and female patients (Ambrosino et al., 1994; Lindsay et al.,
1996; Dall’Ago et al., 2006). We did not have sufficient number
of patients with ischemic and non-ischemic cardiomyopathy
to resolve potential statistical differences due to etiology of
disease. Inspection of data from patients in each group suggest
that overall the changes were consistent for both ischemic and
non-ischemic cardiomyopathy. Nonetheless, in this data set
there is a general trend for exacerbated effects in patients with
FIGURE 4 | Diaphragm protein oxidation in control and patients with end-stage heart failure. (A) Representative lanes of protein gel, carbonyls,
4-hydroxynonenal (4-HNE), and 3-Nitrotyrosines (3-NT). (B) Box and whisker plot shows grouped data from control (n = 3) and all patients with HF (n = 8–11).
(C) Scatter plots show individual data from patients with ischemic and non-ischemic cardiomyopathy. *P < 0.05 by Mann-Whitney test.
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non-ischemic cardiomyopathy. The data from the female HF
patient were consistent with those from males. For instance,
p47phox levels from the female HF patient corresponded to
9.5-fold (mRNA) and 4.5-fold (protein) of the control mean.
The lack of age- and sex-matched data in humans reflects the
nature of our study and focus on the diaphragm that presents
difficulty for obtaining biopsies, especially from control subjects.
(B) Mechanical ventilation: Brain-dead organ donors undergo
mechanical ventilation, which heightens diaphragm protein
oxidation (Betters et al., 2004). We do not have information
on the duration of mechanical ventilation in our control
subjects. It is possible that controls underwent longer periods
of mechanical ventilation than our HF patients experienced
during surgery. However, this would minimize rather than
accentuate differences in the variables that we studied. (C)
Inability to establish cause-and-effect:we cannot establish a causal
relationship between Nox2 levels/activity, protein oxidation, and
diaphragm abnormalities in HF patients. Instead, our data should
serve as an impetus for clinical trials testing selective Nox2
inhibitors or pharmacological antioxidants to treat diaphragm
abnormalities and its associated complications in end-stage HF
patients.
It is worth noting that important studies relying on diaphragm
biopsies of end-stage HF patients and controls also had an
unbalanced distribution of age or sex and included brain-dead
controls or patients with HF due to several causes (Lindsay et al.,
1996; Tikunov et al., 1996, 1997). Finally, we cannot attribute
our findings to proteins within diaphragm muscle cells per se.
In addition to muscle fibers, several other cell types within the
diaphragm express Nox2 subunits, e.g., endothelium, smooth
muscle, and macrophages.
CONCLUSION
Diaphragm of patients with end-stage HF shows upregulation
of Nox2 subunits, increased total but unchanged relative levels
of phosphorylated p47phox, and elevated abundance of catalase.
These changes in ROS-producing and scavenging enzymes
culminated in elevated diaphragm protein oxidation. Overall,
our findings suggest that Nox2 is an important source of ROS
in the diaphragm of patients with end-stage HF and increases
in catalase levels are not sufficient to maintain cellular redox
homeostasis.
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